NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis $8.47 -0.08 (-0.94%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.19▼$8.6950-Day Range$7.48▼$9.6652-Week Range$6.57▼$18.06Volume299,841 shsAverage Volume1.02 million shsMarket Capitalization$833.31 millionP/E RatioN/ADividend YieldN/APrice Target$30.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get 89bio alerts: Email Address 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside255.9% Upside$30.14 Price TargetShort InterestBearish6.95% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.32) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.62 out of 5 starsMedical Sector839th out of 910 stocksPharmaceutical Preparations Industry391st out of 426 stocks 3.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst Coverage89bio has only been the subject of 4 research reports in the past 90 days.Read more about 89bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.95% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in 89bio has recently increased by 5.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 1.9 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 89bio this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of 89bio is held by insiders.Read more about 89bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.32) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 89bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesSeptember 4 at 2:16 AM | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Short Interest Up 5.2% in AugustSeptember 1, 2024 | americanbankingnews.comBrokerages Set 89bio, Inc. (NASDAQ:ETNB) Price Target at $30.14September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 30, 2024 | finance.yahoo.com89bio to Participate in Upcoming Investor ConferencesAugust 18, 2024 | ca.finance.yahoo.comETNB Sep 2024 12.500 callAugust 17, 2024 | ca.finance.yahoo.comETNB Sep 2024 10.000 callAugust 17, 2024 | ca.finance.yahoo.comETNB Sep 2024 7.500 callAugust 9, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio: Promising Pegozafermin Trials and Regulatory ConfidenceAugust 7, 2024 | seekingalpha.com89bio: Bullish In Light Of Further MOA Being Established By PeerAugust 7, 2024 | globenewswire.com89bio Appoints Francis Sarena as Chief Operating OfficerAugust 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising Pegozafermin Clinical TrialsAugust 5, 2024 | markets.businessinsider.com89bio Appoints Charles McWherter, Ph.D., to its Board of DirectorsAugust 5, 2024 | stockhouse.com89bio Reports Second Quarter 2024 Financial Results and Corporate UpdatesAugust 5, 2024 | markets.businessinsider.comETNB Stock Earnings: 89bio Beats EPS for Q2 2024July 12, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 14, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$30.14 High Stock Price Target$53.00 Low Stock Price Target$12.00 Potential Upside/Downside+255.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.42% Return on Assets-31.52% Debt Debt-to-Equity Ratio0.04 Current Ratio13.92 Quick Ratio13.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.23 per share Price / Book1.62Miscellaneous Outstanding Shares98,384,000Free Float95,629,000Market Cap$833.31 million OptionableOptionable Beta1.11 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 58)CEO & Director Comp: $1.06MMr. Quoc Le-Nguyen (Age 56)Chief Technical Operations Officer Comp: $702.87kDr. Harry Mansbach M.D. (Age 59)Chief Medical Officer Comp: $732.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan CPA (Age 58)Senior Vice President of Finance & Principal Accounting Officer Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Melissa AbelSenior Vice President of Commercial StrategyMr. Paul ShinSenior Vice President of R&D OperationsMr. Michael BaldwinVP & Head of QualityMore ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTAlbireo PharmaNASDAQ:ALBOBiohavenNYSE:BHVNHUTCHMEDNASDAQ:HCMRhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 7,203 shares on 8/16/2024Ownership: 0.031%Northwestern Mutual Wealth Management Co.Bought 8,200 shares on 8/16/2024Ownership: 0.008%Millennium Management LLCSold 76,845 shares on 8/15/2024Ownership: 1.027%The Manufacturers Life Insurance Company Bought 3,557 shares on 8/15/2024Ownership: 0.032%ProShare Advisors LLCSold 4,073 shares on 8/14/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions How have ETNB shares performed this year? 89bio's stock was trading at $11.17 at the beginning of the year. Since then, ETNB stock has decreased by 24.2% and is now trading at $8.47. View the best growth stocks for 2024 here. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) posted its earnings results on Monday, August, 5th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. When did 89bio IPO? 89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's top institutional shareholders include Millennium Management LLC (1.03%), Candriam S.C.A. (0.86%), Orchard Capital Management LLC (0.75%) and Integral Health Asset Management LLC (0.46%). Insiders that own company stock include Ra Capital Management, LP, Rohan Palekar, Quoc Le-Nguyen, Ryan Martins, Orbimed Advisors Llc, Kathleen Laporte and Ram Waisbourd. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA) and Procter & Gamble (PG). This page (NASDAQ:ETNB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 89bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.